RPID vs AZTA

For growth investors, Rapid Micro Biosystems, Inc.

(RPID) is the stronger pick with 19. 7% revenue growth year-over-year, versus 3. 6% for Azenta, Inc. (AZTA). Analysts rate Rapid Micro Biosystems, Inc. (RPID) a "Buy" — based on 4 analyst ratings — the highest consensus in this comparison. The "better buy" depends entirely on your goals: growth investors should weight revenue trajectory, value investors should weight P/E and PEG, and income investors should weight dividend yield and streak.

Over the past 5 years, Azenta, Inc.

(AZTA) delivered a total return of -81. 0%, compared to -88. 0% for Rapid Micro Biosystems, Inc. (RPID). Over 10 years, the gap is even starker: AZTA returned +130. 4% versus RPID's -87. 7%. Past returns do not guarantee future results, and the stock with the higher historical return may already have its best growth priced in.

By beta (market sensitivity over 5 years), Azenta, Inc.

(AZTA) is the lower-risk stock at 1. 91β versus Rapid Micro Biosystems, Inc. 's 1. 91β — meaning RPID is approximately 0% more volatile than AZTA relative to the S&P 500. On balance sheet safety, Azenta, Inc. (AZTA) carries a lower debt/equity ratio of 6% versus 72% for Rapid Micro Biosystems, Inc. — giving it more financial flexibility in a downturn.

By revenue growth (latest reported year), Rapid Micro Biosystems, Inc.

(RPID) is pulling ahead at 19. 7% versus 3. 6% for Azenta, Inc. (AZTA). On earnings-per-share growth, the picture is similar: Azenta, Inc. grew EPS 60. 5% year-over-year, compared to 2. 8% for Rapid Micro Biosystems, Inc.. Over a 3-year CAGR, RPID leads at 25. 2% annualised revenue growth. Higher growth typically commands a higher valuation multiple — check whether the premium P/E or P/S is justified by the growth rate using the PEG ratio.

Azenta, Inc.

(AZTA) is the more profitable company, earning -9. 4% net margin versus -140. 3% for Rapid Micro Biosystems, Inc. — meaning it keeps -9. 4% of every revenue dollar as bottom-line profit. Operating margin tells a similar story: AZTA leads at -1. 9% versus -141. 1% for RPID. At the gross margin level — before operating expenses — AZTA leads at 45. 5%, reflecting greater pricing power or product mix advantage. Stronger margins indicate durable pricing power, lower cost of revenue, or higher mix of software/services. They are one of the clearest signs of business quality.

Analyst consensus price targets imply the most upside for RPID: 212.

5% to $8. 00.

None of the stocks in this comparison currently pay a material dividend.

All are effectively zero-yield and should be held for capital appreciation rather than income.

For long-horizon retirement investors, Azenta, Inc.

(AZTA) is the stronger choice — it scores higher on the combination of lower volatility, dividend reliability, and long-term compounding (+130. 4% 10Y return). Rapid Micro Biosystems, Inc. (RPID) carries a higher beta of 1. 91 — meaning larger drawdowns in market downturns, which matters significantly when you cannot wait years for a recovery. Both have compounded well over 10 years (AZTA: +130. 4%, RPID: -87. 7%), confirming both are viable long-term holds — but the lower-volatility option typically results in less emotional selling during corrections. Retirement portfolios generally favour predictability over maximum returns. Consult a financial advisor before making allocation decisions.

Both stocks operate in the Healthcare sector, making this a peer-level intra-sector comparison — the same macro tailwinds and headwinds will affect both.

In terms of investment character: RPID is a small-cap high-growth stock; AZTA is a small-cap quality compounder stock. These fundamental differences mean investors should not choose between them on a single metric — the "better stock" depends entirely on which of these characteristics aligns with your investment strategy.